yes i take peptides · shopping companion
AOD-9604
Category · For EnergyStatus · RUOCitations · 16
The verdict
Mostly no — the marketed use case (fat loss) failed in trials, and the residual use case (joint repair) has only weak human signal.
By source — cost, legality, risk
- BrandNot availableNone — Phase 2b failed in 2007; current GRAS food-additive status (GRN 1057) is not a drug approvalNo FDA-approved AOD-9604 drug; only the food-additive GRAS path exists.
- Compounded 503A pharmacy$150–$300/mo where soldOff-label · failed-trial molecule, not on bulks listMid–high. Compounders shipping AOD do so for a failed-trial indication; legitimacy varies by clinic.
- RUO research peptide$50–$150/moSold 'for research only'Highest. The dominant supply; identity by mass spec is the only check — synthesis quality varies.
- Gray-market raw$20–$27/moUnregulated overseas importCrypto/Wise pay; smaller per-mg variance than the GHRPs but still subject to identity-failure risk.
Stop signals · abort if
- rising IGF-1 (suspect mis-labeled product)
- persistent fasting hyperglycemia
- new joint swelling at injection-adjacent sites
- any allergic reaction
Sources · top 5 of 16
- 01Wilding J. AOD-9604 Metabolic. Current opinion in investigational drugs (London, England : 2000). 2004;5(4):436-40. PMID: 15134286.
- 02Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
- 03Orlovius AK, et al. AOD-9604 does not influence the WADA hGH isoform immunoassay. Drug testing and analysis. 2013;5(11-12):850-2. PMID: 24124033.
- 04Schänzer W, et al. Human sports drug testing by mass spectrometry. Mass spectrometry reviews. 2017;36(1):16-46. PMID: 26213263.
- 05Bayes M, et al. Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology. 2003;25(9):747-71. PMID: 14685303.